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ABSTRACT
Poor outcome for patients with glioblastomas is often associated with 
radioresistance. PI3K/mTOR pathway deregulation has been correlated 
with radioresistance; therefore, PI3K/mTOR inhibition could render tumors 
radiosensitive. In this study, we show that NVP-BEZ235, a dual PI3K/mTOR 
inhibitor, potentiates the effects of irradiation in both adult and pediatric 
glioblastoma cell lines, resulting in early metabolic changes detected by nuclear 
magnetic resonance (NMR) spectroscopy. NVP-BEZ235 radiosensitises cells to X ray 
exposure, inducing cell death through the inhibition of CDC25A and the activation 
of p21cip1(CDKN1A). Lactate and phosphocholine levels, increased with radiation, 
are decreased after NVP-BEZ235 and combination treatment, suggesting that 
inhibiting the PI3K/mTOR pathway reverses radiation induced metabolic changes. 
Importantly, NVP-BEZ235 potentiates the effects of irradiation in a xenograft model 
of adult glioblastoma, where we observed a decrease in lactate and phosphocholine 
levels after seven days of combination treatment. Although tumor size was not 
affected due to the short length of the treatment, a significant increase in CASP3 
mRNA was observed in the combination group. Taken together, our data suggest 
that NMR metabolites could be used as biomarkers to detect an early response to 
combination therapy with PI3K/mTOR inhibitors and radiotherapy in adult and 
pediatric glioblastoma patients.
INTRODUCTION
Glioblastoma (GBM, WHO grade IV) is the most 
common primary malignant brain tumor [1]. Patients with 
newly diagnosed GBM have a median survival of 1 year 
and generally show a poor response to all therapies [2]. 
Histologically, pediatric tumors (pGBM) are identical to 
those arising in adults (aGBM), although the infratentorial 
region is often affected in children and the supratentorial 
area is the most common site in adults [1]. Primary aGBM 
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often have activating mutations in receptor tyrosine kinase 
genes such as EGFR; genes acting in the phosphatidyl 
inositol 3-kinase (PI3K) pathway; and PTEN [3]. 
aGBM and pGBM share some DNA abnormalities [1], 
but mutations in histone H3.3, that occur exclusively in 
pGBM, have recently been identified [4, 5]. The K27M 
mutation is typically seen in brainstem or thalamus tumors 
in younger pediatric patients, while the G34R or G34V 
mutations are present in adolescent patients with tumors 
in supratentorial locations [1, 4].
The current standard of care for newly diagnosed 
GBM is surgery followed by radiotherapy [6]. 
Radiotherapy was the first adjuvant therapy to demonstrate 
a significant survival benefit in aGBM [7] and was 
subsequently also adopted as a standard therapy for 
pGBM. The administration of temozolomide alongside 
radiation [6] is currently the standard regimen for newly 
diagnosed aGBM. This strategy is less effective for 
pGBM patients, with temozolomide adding only a modest 
survival benefit [8].
The outcome for patients remains poor despite 
recent advances in the understanding of GBM biology, 
developments in surgery, chemotherapy and radiotherapy 
[1]. To improve patient survival it is likely that current 
therapies will need to be combined with novel biologically 
targeted therapies, such as a dual blockade of IGFR1 
and PDGFR [9] or mTOR and AKT [10]. Moreover, it 
has been shown that the radioresistance of glioma cells 
can in part be attributed to the deregulation of the PI3K/
mTOR pathway [11] and that p110
α
 isoform specific 
PI3K inhibitors increase the cytotoxic effects of radiation 
therapy in in vitro and in vivo GBM models [12]. One 
rationale for investigating the potential utility of PI3K 
inhibitors as radiosensitising agents is that radiotherapy 
treatment induces DNA double strand breaks, and PI3K 
inhibitors can inhibit proteins involved in the DNA 
damage response. For example, the dual PI3K/mTOR 
inhibitor NVP-BEZ235 has been shown to be active 
against ATM serine/threonine kinase (ATM), ATR serine/
threonine kinase (ATR), and DNA-PK (DNA protein 
kinase) [13], independently of the AKT status [14]. The 
potential of combining irradiation and NVP-BEZ235 
to induce tumor growth shrinkage had been previously 
reported in glioblastoma models (using U87MG cells, 
[15]), as well as in colorectal [16] and prostate cancer [17].
Identifying biomarkers of target inhibition is 
critical for assessing the efficacy of treatment in early 
therapy when tumor shrinkage is not yet detectable, and 
for correlating antitumor effects with target suppression. 
The discovery of new imaging biomarkers is playing 
an increasingly important part in the clinical evaluation 
of molecular therapeutics, as imaging can provide 
information about drug distribution and metabolism 
that otherwise could not be assessed [18]. Non-invasive 
methods are of particular clinical importance in the study 
of brain tumors, as GBMs are often inaccessible and hard 
to biopsy [19, 20]. Nuclear magnetic resonance (NMR) 
spectroscopy, a powerful tool used to non-invasively 
detect cell metabolism [21], is capable of measuring a 
broad range of biological compounds both in vitro and in 
vivo, and is useful for characterizing disease and assessing 
the response to therapy. In vitro or ex vivo 1H-NMR 
can measure levels of lactate, glutamine, glutamate, 
creatine, and many other amino acids. It also enables the 
assessment of choline metabolites, such as phosphocholine 
(PC) and glycerophosphocholine (GPC) levels [21, 22]. 
These are associated with the synthesis and catabolism 
of phosphatidylcholine, contributing to proliferative cell 
growth [23, 24]. NMR can detect significant differences 
in the abundance of choline phospholipid metabolites 
in malignant versus benign lesions in several tumor 
types [25–27]. The high concentration of PC detected 
in cancerous tissue has been found to be due, in part, to 
the stimulation of growth factor-activated Ras and PI3K 
signaling cascades that increase the expression of choline 
kinase alpha (CHKA), the enzyme responsible for choline 
phosphorylation into PC, via the Rho GTPases [28, 29]. 
In line with this, PI3K inhibition was shown to cause a 
decrease in PC in breast, prostate and brain cancer cell 
lines [30–32]. Importantly, lactate and choline metabolites 
can be assessed non-invasively in clinical settings.
The poor patient outcome, combined with the need 
for non-invasive biomarkers, encouraged us to investigate 
whether irradiation potentiation by PI3K/mTOR inhibition 
with NVP-BEZ235 would result in metabolic changes that 
can be evaluated by NMR in pediatric and adult GBM 
models.
Our results confirm previous reports suggesting 
that inhibition of the PI3K/mTOR pathway increases 
the cytotoxic activity of irradiation in both pediatric 
and adult GBM. NMR enables monitoring of metabolic 
changes occurring during this combination treatment, 
suggesting that metabolites, such as PC and lactate, may 
be used as non-invasive biomarkers for the detection of 
response during early stage clinical trials in patients with 
glioblastoma.
RESULTS
PI3K signaling pathway inhibition enhances 
cytotoxic X ray irradiation effects in pGBM and 
aGBM cell lines
The pGBM cell line SF188 and the aGBM cell line 
U87MG were treated with either 5 Gy X ray irradiation, 
2x GI
50
 (drug concentration causing 50 % of growth 
inhibition) NVP-BEZ235 or both treatments in combination 
for 24 h. The largest decrease in the number of SF188 
cells, relative to the untreated control, was observed 
when they were subject to the combination treatment 
(viability following combination =63±13 %, P=0.001; 
viability following NVP-BEZ235 =77±11 %, P=0.006; 
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viability following irradiation =71±9 %; P =0.0002). 
Treatment action was confirmed by Annexin V staining 
where the total number of apoptotic cells increased in 
comparison to the single treatments (Figure 1A&1B). We 
also observed that there was a significant decrease in live 
cells after combination treatment as well as an increase in 
total apoptotic cells compared to NVP-BEZ235 (p≤ 0.028).
In the U87MG cells, a significant decrease in the 
number of U87MG cells was only observed following 
combination treatment (cell viability =88±7 %, P=0.04) 
compared to control. This decrease in the number of viable 
cells was associated with an increase of dead cells (20±2 
%, P=0.0016), propidium iodide (PI) positive and negative 
for Annexin V (Figure 1A&1C). We also observed a 
significant increase in dead cells following combination 
treatment relative to both single agents (p≤ 0.002).
Cell cycle analysis (Figure 2A) showed that NVP-
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We also observed that the mRNA expression of cell 
division cycle 25A (CDC25A), a phosphatase required 
for the progression from G1 to S phase, was also reduced 
after NVP-BEZ235 treatment (Figure 2B, SF188=0.86, 
P
SF188
 =0.04; U87MG=0.22, P
U87MG
<0.001), suggesting 
a possible mechanism for the G1 arrest. As shown in 
Figure 2A, NVP-BEZ235 treatment was sufficient to 





=0.0075). Q-PCR showed 
a significant increase in the level of p21Cip1 (CDKN1A) 
mRNA, a potent cyclin-dependent kinase inhibitor protein 
that regulates cell cycle progression at G1 and S phase 
(Figure 2B), especially in cells receiving the combination 
treatment (SF188=1.54, P
SF188
=0.0013; U87MG= 2.75, 
P
U87MG
<0.0001). For the U87MG cell line such results 
were also confirmed at protein level by immunoblotting 
analysis (Figure 2C). For the SF188 cell line changes in 
protein expression were not evident. This might be due to 
the smaller differences observed at mRNA level compared 
to those detected for the U87MG cell line.
1H-NMR detects metabolic changes after 
combination treatment with NVP-BEZ235 and X 
rays in pGMB and aGMB cell lines in vitro
Next, we used 1H-NMR to identify potential 
biomarkers for monitoring the effect of the PI3K/mTOR 
inhibitor NVP-BEZ235 combined with irradiation on 
pGMB and aGMB cell lines. 1H-NMR aqueous phase 
analysis of metabolites in the SF188 and U87MG cell lines 
showed that metabolic changes observed following single 
agent treatment were still observed after the combination 
treatment (Figure 3).
Supplementary Figure 1 shows examples of the 
1H-NMR spectra of control and treated SF188 cells. 
Treating SF188 cells with NVP-BEZ235 decreased levels 
of lactate (60±17 %, P=0.042), PC (62±12 %, P=0.0009) 
and total choline (tCho: 83±10 %, P=0.045) relative to 
control, but did not affect GPC levels (103±12 %, P=0.58) 
(Figure 3A). In contrast, X ray exposure increased lactate 
(162±65 %, P=0.047), PC (157±21 %, P<0.001), GPC 
(145±28 %, P=0.0021) and tCho (155±28 %, P=0.0001) 
levels. However, pre-treatment of irradiated cells with 
NVP-BEZ235 reversed the X ray induced increase in 
metabolites causing a significant reduction in lactate 
(69±17 %, P=0.038) and PC (82±8 %, P=0.024) levels. 
An increase in the level of GPC (130±24 %) was still 
observed, but it did not reach significance (P=0.08). 
This, together with the decrease in PC levels, resulted in 
no significant change in tCho levels (99±11 %, P=0.9) 
following the combination treatment. Figures 3C and 3D 
show examples of the lactate and the tCho (PC+ GPC+ 
choline) regions of 1H-NMR spectra from control, NVP-
BEZ235-treated, X ray irradiated and combination-treated 
SF188 cells. In the U87MG cell line (Supplementary 
Figure 2 shows the full spectra of control and treated 
U87MG cells) single treatments proved ineffective 
but combination of NVP-BEZ235 treatment and X ray 
irradiation resulted in a significant decrease in lactate 
(41±11 %, P=0.032) and PC (62±15 %, P=0.045) levels 
(Figure 3B). Further experiments showed that NVP-
BEZ235 administered at a higher concentration equivalent 
to 5x GI
50
, could induce significant metabolic changes 
in the U87MG cell line (lactate: 60±26 %, P=0.04; PC: 
72±15 %, P=0.03, viability following NVP-BEZ235 5x 
GI
50
= 86±11 %, P=0.02).
Metabolite expression in conditioned media 
following treatments has been also quantified. For the 
SF188 cell line we observed a significant increase in 
glucose levels following NVP-BEZ235 treatment alone 
(141.8 ± 35.9%, P= 0.0234) and in combination with 
X ray (203.1 ± 27.9%, P= 0.0072), lactate levels were 
decreased without reaching significance. For the U87MG 
cell line, we observed significant reduction in lactate 
following both NVP-BEZ235 (76.4± 8.7 %, P= 0.0032) 
and the combination treatment (79.7± 7.4%, P= 0.0095) 
in conditioned media. Glucose levels were increased 
although without reaching significance.
Enzymes involved in choline and glucose 
metabolism are altered following inhibition of 
the PI3K/mTOR pathway
In SF188 cells, we observed a significant decrease 
in the phosphorylation of RPS6 (Ser240/244) following 
NVP-BEZ235 treatment alone and combined with X 
ray irradiation (Figure 4A, Supplementary Table 1). In 
the U87MG cell line we observed a significant decrease 
in the phosphorylation of AKT (Ser473) and RPS6 
(Ser240/244) following combination of NVP-BEZ235 and 
irradiation (Figure 4A, Supplementary Table 2). Inhibition 
of the PI3K/mTOR pathway leads to the inhibition of 
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several downstream proteins involved in the metabolic 
pathway, which might underpin the observed changes in 
metabolites. In SF188 cells treated with the combination 
treatment we detected a significant decrease in the amount 
of the glycolytic enzyme hexokinase II (HK2) and CHKA 
(Figure 4A, Supplementary Table 1). We also observed a 
Figure 1: NVP-BEZ235 enhances cytotoxic X ray effects in SF188 and U87MG cell lines. (A) Representative dot plots 
showing the response of U87MG and SF188 cell lines to NVP-BEZ235 (2x GI
50
) and X ray (5 Gy). Annexin V staining indicates the 
apoptotic effect. Gates were positioned according to non-stained cells and negative controls. Percentage of live, apoptotic and dead (B) 
SF188 and (C) U87MG cells after treatment with NVP-BEZ235, X rays, alone or in combination (n=3, *P≤0.05, **P≤0.01, ***P≤0.001). 
SF188 ANOVA test: Live P =0.002; Early apoptotic P =0.0015; Late apoptotic P= 0.0151; Tot apoptotic P =0.0015. U87MG ANOVA test: 
Live P =0.0388; Early apoptotic P =0.0296; Total apoptotic P= 0.048, Dead P= 0.0014.
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significant decrease in lactate dehydrogenase A (LDHA) 
mRNA (Figure 4B, P<0.037), suggesting inhibition of 
glycolysis as one of the mechanisms for the depletion 
of lactate seen in our NMR studies. Following X ray 
Figure 2: Effects of combination of NVP-BEZ235 and X ray on cell cycle. (A) Percentage of SF188 and U87MG cells in 
different phase of the cell cycle following treatment with NVP-BEZ235 and X rays, alone or in combination (n=5, *P≤0.05, **P≤0.01, 
***P≤0.001). SF188 ANOVA test: G1 P =0.0017; S P= 0.0001; G2 P= 0.0472. U87MG ANOVA test: G1 P =0.001; S P= 0.0183; G2 P= 
0.0038. (B) Fold change relative to controls in the levels of CDC25A and p21Cip1(CDKN1A) mRNA after treatment of SF188 and U87MG 
cell lines with NVP-BEZ235, X ray, alone or in combination (n=3, *P≤0.05, **P≤0.01, ***P≤0.001). SF188 ANOVA test: CDC25A P 
=0.0283; p21Cip1 P= 0.0018. U87MG ANOVA test: CDC25A P =0.0001; p21Cip1 P≤ 0.0001. (C) Representative immunoblots of CDC25A, 
p21Cip1 in SF188 and U87MG cells following treatment with NVP-BEZ235, X ray or the combination.
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irradiation no changes in the enzymes were observed. In 
the U87MG cell line, a decrease in the expression levels 
of CHKA and HK2 was observed only after combination 
treatment (Figure 4A, Supplementary Table 2). As in 
SF188 cells, the level of LDHA mRNA decreased in the 
U87MG cell lines after treatment with NVP-BEZ235 
alone (P<0.001) or in combination with X rays (Figure 
4B, P<0.003).
Immunofluorescence measurements indicated that in 
the SF188 cell line the decrease in PC observed by NMR 
after NVP-BEZ235 and combination treatment (Figure 
3D) was associated with a decrease in the level of CHKA 
(Figure 4C). Quantitative analysis of CHKA expression 
levels by flow cytometry indicated a decrease to 73±5 % 
(P=0.006) following combination treatment compared to 
the control, while NVP-BEZ235 treatment reduced the 
level of CHKA to 76±9 %, without reaching significance 
(P=0.07). In the U87MG cell line, we observed a decrease 
in the expression of CHKA by immunoblotting only 
following combination treatment.
NMR biomarkers can be identified following 
NVP-BEZ235 / irradiation combination 
treatment in tumor extracts of an aGBM model
We further sought to identify whether our in vitro 
biomarker findings could be translated to an in vivo 
model. Since in vitro experiments had shown that similar 
changes in metabolites occurred in the adult U87MG 
and pediatric SF188 cell lines following combination 
treatment, we established a mouse model of the U87MG 
aGBM cells. Treatments did not affect tumor growth 
within the short time-frame of the experiment but 
analysis of NMR spectra from ex vivo tumor extracts 
(Supplementary Figures 3A&3B) showed changes in the 
levels of metabolites similar to those detected  in vitro. 
Figure 3: 1H-NMR metabolic changes after combination treatment with NVP-BEZ235 and X rays. Quantitative analysis 
of metabolic changes detected by 1H-NMR following 24 h treatment with NVP-BEZ235, X rays or the combination in (A) SF188 and 
(B) U87MG aqueous cell extracts. Data is shown as a percentage of control (n=5, *P≤0.05, **P≤0.01, ***P≤0.001). SF188 ANOVA test: 
lactate P =0.0008; PC P≤ 0.0001; GPC P= 0.0012; tCho P= 0.0001. U87 ANOVA test: lactate P= 0.031, PC P= 0.0018. Expansion of 1H 
MR spectral regions representing (C) lactate and (D) choline-containing metabolites in SF188 aqueous cell extracts.
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Treatment with NVP-BEZ235 caused a decrease in the 
levels of PC (0.2±0.09 µmol/g, P=0.047) and lactate 
(1.6±0.9 µmol/g, P=0.021) compared with the control (PC: 
0.4±0.01 µmol/g, lactate: 3.7±1 µmol/g). Irradiation alone 
did not induce significant changes in the levels of lactate 
and PC (P≥0.5). The combination of NVP-BEZ235 with 
irradiation further decreased the level of lactate (1.4±0.6 
µmol/g, P=0.015) and PC (0.17±0.07 µmol/g, P=0.038). 
Furthermore, we detected a significant decrease in the 
level of GPC (0.4±0.2 µmol/g, P=0.049), tCho (0.6±0.3 
µmol/g, P=0.031) and glutamine (1.6±0.6 µmol/g, 
P=0.05), compared to the vehicle-treated tumors (GPC: 
0.8±0.3 µmol/g, tCho: 1.1±0.5 µmol/g, glutamine: 2.7±0.8 
µmol/g). These changes were not observed with the single 
treatments (Figure 5). A decrease in the percentage of 
phosphorylated RPS6 (relative to total RPS6 - Ser240/244) 
was detected by MSD analysis and confirmed inhibition 
of the PI3K/mTOR pathway (Figure 6A). Q-PCR 
revealed a significant decrease in the amount of LDHA 
mRNA following both administration of NVP-BEZ235 
(P<0.0001) and the combination treatment (P<0.0001). 
We also detected a significant decrease in CHKA mRNA 
(P=0.05) and an increase in CASP3 mRNA (P=0.048) after 
the combination treatment (Figure 6B). Immunoblotting 
confirmed that there was a significant decrease in the 
protein expression levels of LDHA (P=0.005) and CHKA 
(P=0.05) after the combination treatment (Figure 6C, 
Supplementary Table 3). The expression of CHKA also 
decreased following administration of NVP-BEZ235 
alone. In contrast, tumors treated only with irradiation 
had increased levels of LDHA (Figure 6C, Supplementary 
Table 3). Finally, measurements of cleaved PARP showed 
that the combination of NVP-BEZ235 and irradiation 
induced significantly more apoptosis than the single 
treatments (Figure 6C, Supplementary Table 3).
DISCUSSION
The current standard of care for malignant glioma 
is initial treatment with radiation therapy combined with 
Figure 4: Alteration of enzymes involved in metabolism following treatment with NVP-BEZ235 in vitro. (A) Representative 
immunoblots of molecular biomarkers from the PI3K/mTOR pathway, HK2, and CHKA, in SF188 and U87MG cells following treatment 
with NVP-BEZ235, X ray or the combination. (B) Fold change in LDHA mRNA levels compared to the control after treatment in the 
SF188 cells and U87MG cells (n=3, *P≤0.05, **P≤0.01, ***P≤0.001). SF188 ANOVA test: P =0.0122; U87MG ANOVA test: P≤ 0.0001. 
(C) Representative immunofluorescence staining for DAPI (blue) and CHKA (green) in SF188 cells before or after treatment with NVP-
BEZ235, X ray, alone or in combination (magnification 40X).
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temozolomide. However, as GBM usually recur with a 
median time to progression of approximately 7 months 
[6], it is clear that more effective therapies are required. 
Extensive molecular studies have identified several 
genetic events that occur during glioma formation [33], 
such as inactivation of the p53 and Rb tumor suppressor 
pathways and activation of the PI3K pathway. Resistance 
to radiation has been linked to activation of the PI3K 
pathway, as activated AKT accelerates repair of the 
DNA double-strand breaks induced by radiation and, 
consequently, improves post-irradiation cell survival [34, 
35]. Inhibition of the PI3K pathway has been shown to 
have a radiosensitising effect on tumor cells [14, 36], 
therefore PI3K inhibitors combined with radiotherapy 
increase the cytotoxic effect [15]. The results we have 
presented are consistent with previous findings in aGBM 
cell lines such as U87MG [14, 15, 37] and in the pGBM 
cell line SF188 [14] where pretreating with the dual PI3K/
mTOR inhibitor NVP-BEZ235 prior to irradiation results 
in more cell death or apoptosis than the single treatments. 
Here, we show for the first time that these changes are 
associated with early detectable metabolic changes that 
can be monitored by NMR.
We observed that inhibition of the PI3K/mTOR 
pathway induced cell cycle arrest in G1 phase, in both 
U87MG adult and SF188 pediatric glioblastoma cell lines. 
Such arrest can be partly attributed to the inhibition of 
CDC25A and the activation of p21Cip1(CDKN1A) induced 
by NVP-BEZ235. CDC25A is a phosphatase required for 
activation of the G1/S cyclin-dependent kinases CDK4/6, 
enabling cells to progress from G1 to S phase [38]. p21Cip1 
(CDKN1A) is a cyclin-dependent kinase inhibitor which 
promotes G1 cell cycle arrest in response to a variety 
of cellular stresses [39]. It has been reported that DNA 
damage, such as that induced by X rays, can promote G1/S 
and G2/M arrest - with the proportion of cells arresting at 
G1 or G2 depending on the cell type and the checkpoint 
controls operating in the cells [40]. In this study, we 
observed G2/M arrest in both cell lines after irradiation, 
with p21Cip1 (CDKN1A) levels particularly increased in 
U87MG aGBM cells. Such a result is consistent with the 
fact that G2 phase arrest is known to occur in response to 
DNA damage, as it blocks the cell’s entry into mitosis, 
and p21Cip1 is essential to sustain such arrest [41]. The 
dual PI3K/mTOR inhibitor NVP-BEZ235 has been 
reported to be a potent inhibitor of ATM and DNA-PK, 
two of the major kinases involved in the direct response 
to DNA double-strands breaks induced by irradiation [13, 
14]. By modulating the phosphorylation status of ATM, 
NVP-BEZ235 radiosensitizes cells, blocking their DNA 
repair mechanism and forcing them towards apoptosis 
and death [13, 14]. The combination of NVP-BEZ235 and 
Figure 5: NMR biomarkers after NVP-BEZ235 / irradiation combination treatment in tumor extracts of an aGBM 
model. Quantitative analysis of metabolic changes detected by 1H-NMR following treatment of mice bearing U87MG xenografts with 
NVP-BEZ235, irradiation or the combination (n≥6, *P≤0.05, **P≤0.01, ***P≤0.001). ANOVA test: PC P =0.043; tCho P= 0.042; Lactate 
P= 0.0083.
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X ray irradiation induced a G1/S arrest, most likely due 
to a decrease in CDC25A levels. Surprisingly, levels of 
p21Cip1(CDKN1A) RNA were high following combination 
treatment, suggesting a PI3K-independent regulation of 
p21Cip1(CDKN1A) [42]. High levels of p21Cip1 (CDKN1A), 
therefore, are a possible cause of the high mortality 
observed following the combination treatment, as most of 
the cells in G1 arrest (>60% of the total population) will 
continue to apoptosis and death. Moreover, it has been 
previously reported an enhancement of DNA damage 
following NVP-BEZ235 treatment as measured by 
increased expression of histone gamma-H2AX [37].
Our results confirm the potential for combined 
treatments to improve patient outcome and response to 
therapy. Currently, patient response to treatment is assessed 
largely by measuring tumor size by imaging. Although the 
most common techniques used to measure brain tumors 
are CT (computerized tomography) and MRI (magnetic 
resonance imaging), there has been increased interest in 
the development of imaging techniques that could enable 
the early detection of a therapeutic response and predict 
treatment outcome [43]. This is especially true for GBM, 
where the use of non-invasive methods is of considerable 
clinical importance because the location of tumors limits 
accessibility and the repeated use of invasive methods may 
confer significant risk. In this regard, MR spectroscopy 
(MRS) can be used to detect metabolic changes that 
occur early on in a tumor’s response to therapy, and can 
therefore have a role in monitoring treatment outcome 
facilitating personalized medicine [19, 44, 45]. We have 
identified lactate and choline metabolites as potential non-
invasive biomarkers for monitoring the response to PI3K/
mTOR pathway inhibitors, both in pediatric and adult 
glioblastomas. This supports previous in vitro results 
published by us [30–32] and others [46, 47]. However, we 
found the U87MG cell line to be less responsive to NVP-
BEZ235 than SF188, which may be due to the slower 
growth rate of U87MG. Further experiments showed 
that increasing the concentration of NVP-BEZ235 to 5x 
GI
50
 could induce the same changes in metabolite levels 
in U87MG cells that were observed in the SF188 cell 
line. Exposure to radiation induced a significant increase 
in lactate, PC, GPC and total choline in SF188 cells but 
not in U87MG cells, probably due to the variation in 
Figure 6: Enzymatic changes involved in metabolism following treatment with NVP-BEZ235 and X ray in tumor 
extracts of an aGBM model. (A) MSD analysis for pRPS6Ser240/244 in U87MG tumor samples after treatment with NVP-BEZ235, 
irradiation alone in combination (n≥6, *P≤0.05, **P≤0.01, ***P≤0.001). ANOVA test: P= 0.0008. (B) Fold change in levels of LDHA, 
CHKA and CASP3 mRNA after treatment with NVP-BEZ235, irradiation or in combination (n>6, *P≤0.05, **P≤0.01, ***P≤0.001). 
ANOVA test: LDHA P ≤ 0.0001, CHKA P= 0.048, CASP3 P= 0.043. (C) Representative immunoblots showing changes in amounts 
of PARP/Cleaved PARP, LDHA and CHKA in U87MG xenograft tumors following treatment with NVP-BEZ235, irradiation or the 
combination (each lane represents a tumor). Tumors were excised at day 8 after treatment.
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metabolites levels between different samples masking 
changes in the U87MG cells. Importantly, the combination 
of NVP-BEZ235 and radiation induced a decrease in 
lactate and PC in both cell lines, despite the differences 
observed in their basal metabolism (Supplementary Table 
4), and the effects that radiation has on it. This therefore 
suggests that our findings might be relevant for both adult 
and pediatric high grade gliomas independently of their 
different gene expression patterns [48] and of the presence 
of specific oncogenic hotspot mutations unique to pGBM 
[4, 5, 49]. The 2x GI
50
 concentration has been chosen to 
minimize the cytotoxic side effects and to prove that with 
low concentration we can observe early metabolic changes 
by NMR. Cell glycolytic activity was also observed 
by analyzing the expression of lactate and glucose in 
conditioned media following treatments. In both cell lines, 
the combination of NVP-BEZ235 and radiation confirmed 
the obtained results in the cell extracts. An increase in 
glucose levels in the media indicates that glycolytic 
activity is inhibited as cells do not uptake glucose. This 
results in a decrease in both intracellular and extracellular 
levels of lactate.
To consider the potential of translating our findings 
to the clinic, we investigated the effect of combining 
NVP-BEZ235 treatment and irradiation in an in vivo 
model of adult glioblastoma. Typically, it takes between 
2 weeks and 3 months to detect the response of a tumor 
to treatment in in vivo studies [15, 50]. Here, we show 
changes in metabolite levels can be detected by NMR 
after only one week of treatment. This demonstrates 
the potential for NMR to be used to detect the early 
response of glioblastomas to combination therapy before 
any variation in tumor size. In the in vivo settings a low 
concentration of NVP-BEZ235 has been used to reduce 
side effects to undetectable levels. Although tumor size 
was not affected, a significant increase in CASP3 mRNA 
was observed following combination treatment, suggesting 
increased initiation of apoptosis.
Our ex vivo NMR data showed that the combination 
treatment not only decreased lactate and PC by a similar 
proportion to NVP-BEZ235 alone, it also decreased 
glutamine and GPC levels. Moreover, the combined 
reduction in PC and GPC levels led to a decrease in the 
levels of total choline. This result is important for the 
clinical translation of our findings, as a high total choline 
concentration in untreated tumors is generally associated 
with tumor malignancy [19, 45, 51]. Over the past decade 
MRS associated with MRI, has been used routinely in 
the clinic to aid tumor diagnosis. Proton MRS is able to 
distinguish the grade and type of primary brain tumor, and 
inform on grade in prostate and breast malignancies [19, 
45, 52]. Another advantage is that spectroscopic alterations 
are often seen early compared to any variations in tumor 
size during treatment. Different spectral patterns can be 
recorded from responding or non-responding patients and 
can be used to assess the effect of the therapy with the 
final purpose of tailoring a personalized treatment. Our ex 
vivo data are in line with our in vitro results, and clearly 
show that NMR may be used successfully to detect a 
decrease in several metabolites, in particular lactate and 
tCho following inhibition of the PI3K/mTOR pathway and 
radiation treatment of glioblastoma.
The changes we observed in metabolite 
concentrations are a consequence of the regulation of 
cell growth and glucose metabolism by the PI3K/mTOR 
pathway. Via AKT, PI3K activation stimulates glucose 
uptake and flux through the early stages of glycolysis, 
enhancing the expression of glucose transporters and 
HK2 [22]. In line with this, our in vitro experiments 
showed that levels of the glycolytic enzymes HK2 
and LDHA decreased after NVP-BEZ235 treatment 
combined with irradiation, contributing to the observed 
reduction in lactate. Furthermore immunoblotting and 
immunofluorescence analysis showed that the observed 
decrease in PC was associated with a reduction in the 
amount of CHKA [30] in response to treatment with NVP-
BEZ235 alone and combined with X ray irradiation. Also 
quantitative FACS analysis confirmed that this reduction 
is significant following the combination treatment. On the 
other hand, the increase in lactate and choline metabolites 
observed following X ray irradiation was not associated 
with an increase in the protein expression levels of 
HK2 and LDHA or CHKA, indicating that different 
mechanisms could be responsible for these changes. PC 
and GPC increase could be caused by breakdown of cell 
membranes due cytotoxicity caused by the irradiation, 
as previously reported [30, 31, 53]. Several papers have 
described an increase in lactate following irradiation, 
but as described by Liao et al. this might be due to an 
enhanced LDHA activity rather than an increment 
in protein expression [54]. Elevated glycolysis and a 
subsequent elevated production of lactate, as cell response 
to radiation, might also facilitate DNA double strand break 
repair [55]. Pre-treatment with NVP-BEZ235 reverses the 
effects of irradiation, causing metabolic changes similar to 
those observed with treatment with NVP-BEZ235 alone, 
indicating that the observed metabolic changes and the 
associated inhibition of metabolic enzymes are mainly a 
consequence of the inhibition of the PI3K/mTOR pathway, 
ruling out non-specific, anti-proliferative effects associated 
with cytotoxicity.
Our in vitro findings are confirmed on excised tumor 
xenografts by Q-PCR showing a significant reduction in 
the abundance of the LDHA transcript following NVP-
BEZ235 and the combination treatment. Furthermore, a 
decrease in the level of the CHKA transcript was detected 
following the combination treatment. It is important 
that despite the absence of effects of X ray irradiation 
on metabolism, it is not interfering with the effects of 
NVP-BEZ235 and we can still detect the inhibition of 
enzymes such as LDHA, HK2, CHKA and the associated 
decrease in lactate and choline metabolites and hence 
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these metabolic changes may have potential as biomarkers 
for the PI3K pathway inhibition in combination with 
irradiation.
Taken together, our results show that inhibition 
of the PI3K/mTOR pathway makes adult and pediatric 
glioma cells more sensitive to radiation. More importantly, 
the response to treatment can be detected early by NMR, 
before tumor size is affected. Treatment induced cell 
death is associated with changes in the levels of metabolic 
biomarkers, such as lactate and choline, that could 
predict tumor response. To our knowledge, this is the 
first study showing that a PI3K inhibitor combined with 
radiation induces metabolic changes in adult and pediatric 
glioblastoma cells. In the clinical setting, the metabolites 
we have identified here may have potential for use as non-
invasive biomarkers to detect a tumor response prior to 
detecting any changes in tumor size. In turn, this should 
enable clinicians to personalize the treatment of adult and 
pediatric patients affected by glioma, which at the moment 
is a disease with a very poor prognosis.
MATERIALS AND METHODS
Cell culture and treatment
The human adult U87MG (PTEN null) and pediatric 
SF188 (WT PTEN, PIK3CA and histone H3.3 (H3F3A) 
G34V) glioblastoma cell lines (WHO grade IV) were grown 
as monolayers in DMEM + Glutamax (Gibco, Carlsbad, 
CA, USA) and DMEM/F12 Ham’s (Sigma, St. Louis, 
MO, USA) medium respectively, supplemented with 10% 
FCS (fetal calf serum, Gibco, Carlsbad, CA, USA) and 
maintained at 5% CO2. Both cell lines have been kindly 
donated by Dr. C. Jones and authenticated by STR profiling 
(02/2015 for the U87MG, and 03/2016 for the SF188). Cell 
viability was judged by trypan blue exclusion.
The GI
50
 value for the dual pan-Class I PI3K/mTOR 
inhibitor NVP-BEZ235 (Novartis, Basel, Switzerland) 
was determined using a cell titre blue assay (Promega, 
Madison, WI, USA). Both cell lines were treated with 
2x GI
50
 NVP-BEZ235 as a single treatment (U87MG 
GI
50
 = 35.7nM, SF188 GI
50
 = 14nM) for 24 h. When 
given as part of a combined treatment, NVP-BEZ235 (2x 
GI
50
) was administered 1 h prior to X ray irradiation (5 
Gy, AGO X ray HS 320Kv set, AGO Installations Ltd) 
then maintained for 24 h. The effect of treatment on cell 
number was monitored by counting the number of viable 
attached cells in a treated flask and comparing that number 
with the number of attached cells in a control flask. Cell 
viability was evaluated using the Annexin V & Cell death 
Assay (Muse, Millipore, Billerica, MA, USA) following 
the manufacturer’s instructions.
Flow cytometry
Cell cycle analysis was performed as previously 
described [56]. Acquisitions were performed using a BD 
LSRII flow cytometer. Cell cycle data were analyzed using 
FlowJo software (Ashland).
Xenograft studies
All experimental procedures on animals were carried 
out in accordance with U.K. Home Office regulations 
under the Animals (Scientific Procedures) Act 1986 and 
UK National Cancer Research Institute (NCRI) Guidelines 
for the Welfare and Use of Animals in Cancer Research 
[57]. U87MG cells (2x 106 in 200 µl of HBSS, Hanks' 
Balanced Salt Solution, Gibco, Carlsbad, CA, USA) 
were delivered subcutaneously into athymic nude mice, 
NCr-Foxn1nu (female, 6 weeks old, 20g, Taconic, Albany, 
NY, USA). When tumors reached a volume of 200 mm3, 
mice were randomly divided into four cohorts: vehicle, 
NVP-BEZ235, irradiation, and combined NVP-BEZ235 + 
irradiation treatment. NVP-BEZ235 (45 mg/kg) or vehicle 
administration (N-methyl-2-pyrrolidone combined with 
Polyethylene glycol, Sigma, St. Louis, MO, USA) was 
given p.o. on days 1, 3, 5 and 7. Irradiation (2 Gy/dose) 
was given on days 2, 4 and 6 using a single Caesium137 
source (Gammacel 40 Exactor, Best Teratonic). Animals 
were euthanized at day 8 and tumors were snap-frozen 
in liquid nitrogen for ex vivo NMR and immunoblotting 
analysis.
Immunoblotting and MSD analysis
Immunodetection was performed using antibodies 
against pAKT (Ser473), total AKT, pRPS6 (Ser240/244), 
total RPS6, hexokinase II (HK2, Cell Signaling, Beverly, 
MA, USA), CHKA (Sigma), p21Cip1 (Cell Signaling), 
Cdc25A (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) and GAPDH (Chemicon, Billerica, MA, USA). 
Blots were revealed with peroxidase-conjugated secondary 
anti-rabbit antibody (GE Healthcare, Chalfont St. Giles, 
UK) followed by ECL chemiluminescence solution 
(Amersham Biosciences, St. Giles, UK). The western blot 
procedure used for the tumor extracts was the same used 
for the cell lines.
An MSD assay, more sensitive than immunoblots 
with tissue extracts, was used to identify target inhibition 
ex vivo in tissue samples. It was based on a previously 
described protocol with minor modifications [58]. The 
protein concentration was determined using a Direct 
Detect spectrophotometer according to the manufacturer’s 
instructions.
RNA extraction and RT-PCR
Total cellular RNA was extracted using a QIAamp 
RNeasy mini extraction kit (Qiagen, Hilden, Germany). 
Tumor RNA was extracted using a RecoverAll™ Total 
Nucleic Acid Isolation Kit for FFPE (Ambion, Foster 
City, CA, USA). To generate cDNA, 1000 ng of total 
RNA was reverse transcribed using a high capacity 
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cDNA reverse transcription kit (Applied BioSystems, 
Carlsbad, CA, USA). Real-time RT-PCR analysis was 
performed to quantify LDHA (Hs00855332_g1), CDC25A 
(Hs00947994_m1), p21cip1(CDKN1A) (Hs00355782_m1), 
CASP3 (Hs00234387_m1) and CHKA (Hs00957875_
m1) mRNA using a TaqMan fast advanced master mix 
(Applied BioSystems, Carlsbad, CA, USA) following 
manufacturer's instructions.
1H-NMR of cell and tumor extracts
To obtain an NMR spectrum, an average of 3x107 
cells in logarithmic phase was extracted from cell culture 
using the dual phase extraction method [56]. Snap-frozen 
excised tumors had been reduced to a cell suspension and 
were then treated as cell culture samples. Lyophilized 
samples of the water soluble fraction were reconstituted 
in deuterium oxide (D2O). 
1H-NMR spectra were acquired 
as previously described [56]. Metabolite contents were 
determined by integration and normalized relative to the 
peak integral of an internal reference (TSP 0.15%) and 
corrected for signal intensity saturation and the number of 
cells extracted per sample, or the tumor weight.
Immunofluorescence (IF)
Cells, grown on glass coverslips in 24 well 
plates and treated as described above, were fixed in 
4% paraformaldehyde, permeabilized with Triton and 
incubated with primary (CHKA, Sigma, St. Louis, MO, 
USA) and secondary antibody (anti-Rabbit, Alexa Fluor 
488, Cell Signaling, Beverly, MA, USA) for 1 h each 
at 4°C. Images were captured with a Zeiss confocal 
microscope LSM700 and analyzed with the Zen2009 
software.
Statistical analysis
Box and whiskers plots divide the data set into 
quartiles to display sample variability and degree of 
dispersion (line at median) ± S.D. Histograms are 
expressed as mean ± S.D. One way ANOVA test was 
used to verify the statistical significance of the results, 
with a p-value of ≤ 0.05 considered to be significant. All 
experiments are n ≥ 3.
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